Drugs / Elsiglutide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01543451 | Feb 2012 → Jan 2013 | diarrheal disease | Helsinn Healthcare SA | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02383810 Comparator | Jan 2015 → Feb 2016 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elsiglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01543451 ↗ |
| Known as | Elsiglutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108318 ↗ |
| Known as | ZP1846 | “Elsiglutide (ZP1846)Administered s.c.” NCT01543451 ↗ |
| Action | Activate | “Glucagon-like peptide 2 receptor agonist” CHEMBL2108318 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108318 ↗ |
| Route | Subcutaneous | “Elsiglutide (ZP1846)Administered s.c.” NCT01543451 ↗ |
| Target | GLP2R | “Glucagon-like peptide 2 receptor agonist” CHEMBL2108318 ↗ |